INTF - ETF AI Analysis

Top Page

iShares MSCI Intl Multifactor ETF (INTF)

Rating:65Neutral

Price Target:―

INTF, the iShares MSCI Intl Multifactor ETF, earns a solid overall rating thanks to high-quality global leaders like Novartis, AstraZeneca, ASML, and HSBC, which bring strong financial performance, healthy balance sheets, and generally positive outlooks to the portfolio. These strengths are slightly tempered by holdings such as BHP and Rio Tinto, where short-term bearish momentum or recent revenue and cash flow pressures introduce some risk, and by pockets of potentially overvalued names, making valuation and sector-specific slowdowns the main factors that can hold back the fund’s rating.

Positive Factors

Broad International Diversification

The fund spreads its investments across many countries, with meaningful exposure to Japan, the UK, and several major European markets, which helps reduce reliance on any single economy.

Balanced Sector Mix

Holdings are spread across financials, industrials, consumer, technology, health care, and other sectors, helping to cushion the impact if one industry struggles.

Competitive Expense Ratio

The ETF charges a relatively low fee, so less of your potential return is lost to ongoing costs.

Negative Factors

Heavy Tilt Toward Financials

Financial stocks make up a large share of the portfolio, which can increase sensitivity to interest rate changes and banking sector stress.

Mixed Performance Among Top Holdings

While some major positions like ASML and Mitsubishi UFJ have shown strong gains, others such as Nestlé, Royal Bank of Canada, and AstraZeneca have been weaker, creating uneven contribution to returns.

Limited U.S. Market Exposure

The fund has only a small allocation to U.S. stocks, so investors who want significant exposure to the U.S. market would need to pair this ETF with other holdings.

INTF vs. SPDR S&P 500 ETF (SPY)

AUM3.15B

RegionDeveloped Markets

Expense Ratio0.16%

Beta0.73

IssueriShares

Inception DateApr 28, 2015

Dividend Yield2.77%

Asset ClassEquity

Index TrackedSTOXX International Equity Factor

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume219,831

30 Day Avg. Volume211,612

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

43.70

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering463

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

INTF Summary

INTF is the iShares MSCI Intl Multifactor ETF, which follows the STOXX International Equity Factor index. It invests in a wide mix of companies outside the U.S., with big exposure to countries like Japan, the UK, and France, and sectors such as financials and industrials. Well-known holdings include Novartis and ASML. The fund uses a rules-based approach to pick stocks it sees as higher quality or better value, which may help with long-term growth and diversification beyond the U.S. stock market. A key risk is that international stocks can be volatile and are affected by currency and global economic swings.

How much will it cost me?The iShares MSCI Intl Multifactor ETF (INTF) has an expense ratio of 0.16%, which means you’ll pay $1.60 per year for every $1,000 invested. This is lower than average because it’s passively managed, focusing on tracking a multifactor index rather than active stock selection.

What would affect this ETF?The iShares MSCI Intl Multifactor ETF (INTF) could benefit from growth in developed markets outside the U.S., especially if sectors like financials and technology perform well, as they make up a significant portion of the fund. However, challenges such as rising interest rates or economic slowdowns in these regions could negatively impact key holdings like Novartis and ASML, as well as broader sector performance. Regulatory changes or geopolitical tensions in developed markets may also influence the ETF's future returns.

INTF Top 10 Holdings

INTF is leaning heavily on a mix of European pharma and global financial giants to do the heavy lifting. Novartis, Roche, and AstraZeneca are all rising, giving the fund a solid health care backbone, while Nestlé adds a steady, defensive anchor. On the growth side, ASML has been a standout, riding strong momentum in chip equipment. Financials like Royal Bank of Canada, Mitsubishi UFJ, Mizuho, and HSBC are also climbing rather than dragging, underscoring the fund’s tilt toward developed markets outside the U.S., with no single stock dominating the story.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
NOVN	Novartis AG	2.32%	$72.44M	CHF237.56B	22.14%	80 Outperform
ASML	ASML Holding NV	2.02%	$62.94M	€453.03B	72.70%	76 Outperform
ROG	Roche Holding AG	1.16%	$36.25M	CHF281.05B	26.73%	73 Outperform
NESN	Nestlé SA	1.05%	$32.78M	CHF202.69B	0.58%	71 Outperform
AZN	AstraZeneca	1.02%	$31.75M	$306.87B	20.11%	80 Outperform
RY	Royal Bank Of Canada	1.02%	$31.72M	$231.31B	42.10%	75 Outperform
ABB	ABB Ltd	0.96%	$30.03M	kr1.43T	33.72%	78 Outperform
HSBA	HSBC Holdings	0.89%	$27.77M	£219.64B	42.06%	80 Outperform
LBLCF	Loblaw Companies	0.85%	$26.56M	$53.44B	37.73%	76 Outperform
8306	Mitsubishi UFJ Financial Group	0.84%	$26.14M	¥30.58T	25.81%	76 Outperform

INTF Technical Analysis

Technical Analysis Sentiment

Negative

Last Price―

Price Trends

50DMA

39.75

Negative

100DMA

37.99

Positive

200DMA

36.10

Positive

Market Momentum

MACD

0.02

Positive

RSI

36.53

Neutral

STOCH

26.06

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For INTF, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 40.93, equal to the 50-day MA of 39.75, and equal to the 200-day MA of 36.10, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 36.53 is Neutral, neither overbought nor oversold. The STOCH value of 26.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INTF.

INTF Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
INTF	―	―	$3.15B	0.16%	65 Neutral
GSIE	―	―	$5.25B	0.25%	66 Neutral
LVHI	―	―	$4.53B	0.40%	70 Outperform
IMTM	―	―	$3.66B	0.30%	69 Neutral
IDMO	―	―	$3.25B	0.25%	68 Neutral
PXF	―	―	$2.60B	0.43%	60 Neutral

Performance Comparison

INTF

iShares MSCI Intl Multifactor ETF

39.05

8.88

29.43%

GSIE

Goldman Sachs ActiveBeta International Equity ETF

―

LVHI

Legg Mason International Low Volatility High Dividend ETF

―

IMTM

iShares MSCI Intl Momentum Factor ETF

―

IDMO

Invesco S&P International Developed Momentum ETF

―

PXF

Invesco FTSE RAFI Developed Markets ex-U.S. ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents